Replimune Group Inc (REPL)

10:03 AM

Will Replimune Group Inc. stock sustain high P E ratiosMarket Volume Report & Free Weekly Watchlist of Top Performers - Trung tâm Dự báo KTTV quốc gia

10:03 AM

03:26 AM

What to do if you’re stuck in Replimune Group Inc.CPI Data & Comprehensive Market Scan Insights - newser.com

03:26 AM

12:52 PM

How Replimune Group Inc. stock compares to growth peers2025 Market Sentiment & Real-Time Stock Price Movement Reports - newser.com

12:52 PM

Oct 16, 2025

Will earnings trigger a reversal in Replimune Group Inc.Insider Buying & Weekly Watchlist for Consistent Profits - newser.com

Oct 16, 2025

Oct 15, 2025

How to build a custom watchlist for Replimune Group Inc.July 2025 Market Mood & Safe Entry Point Alerts - newser.com

Oct 15, 2025

Oct 13, 2025

Why Replimune Group Inc. is moving todayMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com

Oct 13, 2025

Oct 12, 2025

Real time social sentiment graph for Replimune Group Inc.Earnings Performance Report & Real-Time Chart Breakout Alerts - newser.com

Oct 12, 2025

Oct 10, 2025

Forecasting Replimune Group Inc. price range with options data2025 Technical Patterns & Risk Managed Investment Signals - newser.com

Oct 10, 2025

Oct 10, 2025

How to use a screener to detect Replimune Group Inc. breakoutsInsider Selling & Technical Entry and Exit Tips - newser.com

Oct 10, 2025

Oct 10, 2025

Replimune Group, Inc. (REPL) Stock Analysis: Navigating the Biotech Frontier with Oncolytic Immunotherapies - DirectorsTalk Interviews

Oct 10, 2025

Oct 10, 2025

Will Replimune Group Inc. stock go up soon2025 Dividend Review & Technical Confirmation Trade Alerts - newser.com

Oct 10, 2025

Oct 09, 2025

Tools to assess Replimune Group Inc.’s risk profileMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com

Oct 09, 2025

Oct 09, 2025

Will a bounce in Replimune Group Inc. offer an exit2025 Pullback Review & Capital Efficient Trade Techniques - newser.com

Oct 09, 2025

Oct 08, 2025

Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles By Investing.com - Investing.com South Africa

Oct 08, 2025

Oct 08, 2025

Replimune’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com

Oct 08, 2025

Oct 08, 2025

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Oct 08, 2025

Oct 05, 2025

Published on: 2025-10-05 07:01:13 - newser.com

Oct 05, 2025

Oct 05, 2025

What does recent volatility data suggest for Replimune Group Inc.2025 Investor Takeaways & Growth Focused Stock Pick Reports - newser.com

Oct 05, 2025

Oct 05, 2025

Why retail investors pile into Replimune Group Inc. stock2025 EndofYear Setup & Free Fast Gain Swing Trade Alerts - newser.com

Oct 05, 2025

Oct 03, 2025

Published on: 2025-10-03 06:54:08 - newser.com

Oct 03, 2025

Oct 03, 2025

Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from Analysts - MarketBeat

Oct 03, 2025

Oct 03, 2025

Strategies to average down on Replimune Group Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com

Oct 03, 2025

Sep 26, 2025

Replimune Faces Big Swings After FDA Setback And Cash Concerns - Finimize

Sep 26, 2025

Sep 24, 2025

Join the Replimune Group (REPL) Securities Fraud Lawsuit Investigation - Claim Depot

Sep 24, 2025

Sep 24, 2025

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug - TradingView

Sep 24, 2025

Sep 23, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - WV News

Sep 23, 2025

Sep 23, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Sep 23, 2025

Sep 22, 2025

REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Sep 22, 2025